Abzena has introduced the AbZelect™ and AbZelectPRO™ platforms for accelerating the generation of production cell lines used in the manufacturing of antibodies and recombinant proteins. These platforms empower Abzena to expedite the progression of complex biologic drug programs to clinical trials, minimizing risks on the path to submitting Investigational New Drug (IND) applications.
The AbZelect™ and AbZelectPRO™ platforms facilitate the swift generation and selection of high-yielding mammalian CHO cell lines dedicated to therapeutic protein and recombinant vaccine production. Specifically designed for conventional protein programs like antibodies, Abzena's proprietary, license-free AbZelect™ is optimized in vector, host cell line, and process, resulting in improved cell doubling times, viable cell densities, and the creation of robust and stable cell lines. For maximal production levels, AbZelectPRO™ combines AbZelect™ with ProteoNic's 2G UNic® premium vector technology, enhancing expression levels and generating stable cell lines capable of producing proteins such as bispecifics, fusion proteins, and other innovative modalities.
By streamlining the Cell Line Development (CLD) process, these platforms reduce timelines from DNA to research cell banks to just 15 weeks, exhibiting exceptional productivity levels. Both platforms offer cost efficiencies and flexibility to mitigate risks in biologics development, encompassing rapid material production, technology transfer, scale-up, and manufacturing, all within a unified organization.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!